Regeneron's new take on bispecifics: activating complement

Regeneron's new bispecific antibodies for the first time tap the complement system -- going beyond the immune cells traditionally targeted, and expanding the modality into new patient populations and indications.

With proof of concept studies against bacteria as well as cancer, the data advance the possibility that bispecifics could add to the sorely needed armamentarium of agents to overcome antimicrobial resistance...